Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ECG vs CDNL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ECG Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

ECG Overall Winner 6-Pillar Tally: ECG 6 – 0 CDNL Matrix Metrics: ECG 10 – 0 CDNL

As of Nov 20, 2026, Everus Construction Group, Inc. (ECG) is the stronger overall head-to-head candidate over CDNL (CDNL) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ECG carries a Unified Composite Score of 50.0/100 (HOLD) at $76.59 (10.8x Forward P/E, 8.2% operating margin), whereas CDNL carries 44.2/100 (HOLD) at $4.75 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: ECG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.6); meanwhile CDNL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ECG vs CDNL
ECG NYSE Head-to-Head Winner
Everus Construction Group, Inc.
Operative Builders
$76.59
-8.66% 1D
Market Cap $4.3B
TTM Revenue $4.66B
Forward P/E 10.8x
Beta / 30D Vol 2.17β · 127% Vol
Unified Composite Score
50.0 / 100 HOLD
Tech 73.0 Fund 64.0 Flow 55.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.7%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $90.35 · SMA50: $105.19
CDNL US Equity
CDNL
Institutional Equity
$4.75
-8.4% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.65β · 238% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 45.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.9%), weak momentum, RSI 23
RSI-14: 22.9 · SMA20: $11.67 · SMA50: $19.54

6-Pillar Scorecard Institutional Category Breakdown (ECG 6 – 0 CDNL)

Columns: Metric · ECG · CDNL
1. Valuation Multiples ECG
Forward P/E 10.8x N/M
Trailing P/E 15.1x N/M
PEG Ratio N/M N/M
EV / Revenue 1.0x N/M
2. Growth & Scale ECG
Revenue Growth (YoY) +40.3% N/A
Earnings Growth (YoY) +61.3% N/A
TTM Revenue (USD) $4.66B N/A
Market Cap $4.3B N/A
3. Profitability & Quality ECG
Gross Margin 13.6% N/A
Operating Margin 8.2% N/A
Net Profit Margin 6.2% N/A
Return on Equity (ROE) 40.3% N/A
4. Balance Sheet & Cash Flow ECG
Cash Generation (TTM) $237M N/A
Cash Flow Margin 5.1% N/A
Net Cash / Leverage $439M Net Debt (0.81x D/E) N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ECG
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 69.2% (6th %ile) N/A (N/A)
Put/Call OI Skew 8.85x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ECG
OpEx & R&D Intensity 5.4% of Rev ($252M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Engineering & Construction Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ECG (10) vs CDNL (0)
Institutional Metric ECG CDNL Criterion Row Edge
Market Capitalization
Scale
$4.3B N/A Larger Scale ECG
Trailing P/E Ratio
Valuation
15.1x N/M Lower Multiple ECG
Forward P/E Ratio
Valuation
10.8x N/M Lower Multiple ECG
Revenue Growth (YoY)
Growth
+40.3% N/A Higher Growth ECG
Operating Margin (TTM)
Profitability
8.2% N/A Higher Margin ECG
Net Profit Margin
Profitability
6.2% N/A Higher Margin ECG
Return on Equity (ROE)
Capital Efficiency
40.3% N/A Higher ROE ECG
52-Week Range Position
Momentum
6% ($70–$172) 0% ($5–$96) Stronger Trend ECG
Beta / 30D Volatility
Risk Regime
2.17β · 127% Vol 2.65β · 238% Vol Lower Realized Risk ECG
Unified Institutional Score
Composite Signal
50.0 / 100 (HOLD) 44.2 / 100 (HOLD) Higher Composite ECG
Trailing 12M Revenue (USD)
Operating Scale
$4.66B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
13.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$237M ($439M Net Debt (0.81x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ECG +44.26 pp
ECG: -21.08% · CDNL: -65.34%
3M Horizon ECG +52.05 pp
ECG: -36.44% · CDNL: -88.49%
6M Horizon ECG +41.81 pp
ECG: -48.48% · CDNL: -90.29%
1Y Horizon ECG +61.76 pp
ECG: -17.81% · CDNL: -79.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ECG vs CDNL. Trailing 12-month operating profitability (ECG 8.2% vs CDNL N/A) and valuation multiples (ECG 10.8x vs CDNL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ECG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.66B
Gross Margin13.6%
Op. Margin8.2%
ROE / Fwd P/E40.3% · 10.8x
CDNL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ECG BREAKDOWN
138d in phase · OBV NEUTRAL
Current IV 69.2%
IV Percentile 6th %ile
Put/Call OI Skew 8.85x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ECG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDNL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDNL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ECG Moat Profile High-Margin Pricing Power Moat
Engineering & Construction Operator
Competes within the Engineering & Construction value chain with $4.3B market capitalization and 8.2% operating margin.
OpEx & R&D Reinvestment 5.4% of Rev ($252M)
90D Engineering Disclosures 0 Published
CDNL Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ECG vs CDNL Key Questions & Quantitative Answers

As of Nov 20, 2026, Everus Construction Group, Inc. (ECG) is the stronger overall head-to-head candidate over CDNL (CDNL) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ECG carries a Unified Composite Score of 50.0/100 (HOLD) at $76.59 (10.8x Forward P/E, 8.2% operating margin), whereas CDNL carries 44.2/100 (HOLD) at $4.75 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: ECG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.6); meanwhile CDNL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ECG leads the Growth & Scale pillar: ECG posts +40.3% YoY revenue growth and +61.3% YoY earnings growth on $4.66B TTM revenue (13.6% gross margin, 8.2% operating margin), compared with CDNL at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ECG generates $4.66B in USD-normalized revenue versus N/A for CDNL. In operating R&D and SG&A reinvestment, ECG deploys 5.4% of Rev ($252M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CDNL.

ECG screens cheaper on headline valuation multiples. ECG trades at 10.8x Forward P/E, 15.1x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (5.1% FCF margin), whereas CDNL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECG (40.3% ROE) versus CDNL (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ECG carries 69.2% implied volatility (6th %ile, Compressed (<25th %ile)), a 8.85x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.17β · 127% Vol realized risk). By comparison, CDNL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.65β · 238% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.